FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978155012> ?p ?o ?g. }

• W1978155012 endingPage "1651" @default.
• W1978155012 startingPage "1641" @default.
• W1978155012 abstract "Insulin is recommended as a second-line treatment after diet and metformin fail to reach and/or maintain glycemic targets considered to minimize the risk for long-term diabetic complications. Hypoglycemia and the fear of developing hypoglyce-mia, however, remain substantial barriers to the initiation and optimal use of insulin.The aim of this study was to compare biphasic insulin aspart 30 (BIAsp 30) with biphasic human insulin 30 (BHI 30) with respect to glycemic control and the risk for hypoglycemia using a meta-analysis of clinical trials comparing these insulins in patients with type 2 diabetes mellitus (T2DM).We included all published and unpublished, randomized, controlled trials in adult patients with T2DM (treatment duration > or = 12 weeks) for which individual patient data were available. All clinical databases and local trial registries of Novo Nordisk A/S (Soeborg, Denmark) were searched to identify clinical trials comparing the 2 products. The predefined primary end point of the study was the overall rate of nocturnal hypoglyce-mia (major, minor, and symptoms-only hypoglycemia occurring from 12:00-6:00 AM). Hypoglycemia was analyzed using a negative binomial distribution model, accounting for exposure time. Glycemic end points were analyzed at 12 to 16 weeks of treatment using ANCOVA, adjusting for baseline. Secondary safety end points were the rates of major hypoglycemia (hypoglycemia requiring third-party assistance), minor hypoglycemia (symptoms confirmed by plasma glucose [PG] <3.1 mmol/L), daytime hypoglycemia (major, minor, and symptoms-only hypoglycemia occurring from 6:01 AM-11:59 PM), overall hypoglycemia (the sum of all major, minor, and symptoms-only episodes), and change in weight from baseline to 12 to 16 weeks of treatment. Secondary efficacy end points were changes in glycosylated hemoglobin (HbA(1c)), fasting PG (FPG), postprandial PG increment (averaged over breakfast, lunch, and dinner), and insulin dose.Nine randomized, parallel or crossover trials were included (N = 1674; male sex, 57%; mean [SD] age, 61.0 [10.6] years; body mass index, 26.7 [4.6] kg/m(2); HbA(1c), 8.1% [1.4%]; duration of diabetes, 10.9 [7.9] years). Rates of overall hypoglycemia were not significantly different (rate ratio [RR] = 1.08; 95% CI, 0.94-1.24; P = NS) between treatments. BIAsp 30 had a 50% lower rate of nocturnal hypoglycemia than BHI 30 (RR = 0.50; 95% CI, 0.38-0.67; P < 0.01), whereas the rate of daytime hypoglycemia was 24% lower for BHI 30 (RR = 1.24; 95% CI, 1.08-1.43; P < 0.01). The likelihood of major hypo-glycemia was significantly lower with BIAsp 30 compared with BHI 30 (odds ratio = 0.45; 95% CI, 0.22-0.93; P < 0.05). BIAsp 30 was associated with reduced PPG increment (averaged over breakfast, lunch and dinner) compared with BHI 30 (treatment difference, -0.31; 95% CI, -0.49 to -0.07; P < 0.01). There was a significantly larger reduction in FPG associated with BHI 30 (treatment difference, 0.63; 95% CI, 0.31-0.95; P < 0.01). However, no significant treatment difference was found for HbA(1c) (treatment difference, 0.04; 95% CI, -0.02 to 0.10; P = NS).This meta-analysis found BIAsp 30 to be associated with a significantly lower rate of nocturnal and major hypoglycemia, but a significantly increased risk for daytime hypoglycemia, compared with BHI 30 at a similar level of HbA(1c) in patients with T2DM." @default.
• W1978155012 created "2016-06-24" @default.
• W1978155012 creator A5003855926 @default.
• W1978155012 creator A5012973322 @default.
• W1978155012 creator A5031396369 @default.
• W1978155012 creator A5032317621 @default.
• W1978155012 creator A5043093313 @default.
• W1978155012 creator A5055936518 @default.
• W1978155012 creator A5066686056 @default.
• W1978155012 creator A5081667069 @default.
• W1978155012 date "2009-08-01" @default.
• W1978155012 modified "2023-10-05" @default.
• W1978155012 title "Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis" @default.
• W1978155012 cites W1512877138 @default.
• W1978155012 cites W1978088403 @default.
• W1978155012 cites W1985958519 @default.
• W1978155012 cites W2004910803 @default.
• W1978155012 cites W2011709544 @default.
• W1978155012 cites W2035042051 @default.
• W1978155012 cites W2043598123 @default.
• W1978155012 cites W2072585011 @default.
• W1978155012 cites W2073453161 @default.
• W1978155012 cites W2077681546 @default.
• W1978155012 cites W2080848416 @default.
• W1978155012 cites W2101930436 @default.
• W1978155012 cites W2108927215 @default.
• W1978155012 cites W2125435699 @default.
• W1978155012 cites W2128499867 @default.
• W1978155012 cites W2146901298 @default.
• W1978155012 cites W2150939399 @default.
• W1978155012 cites W2153449155 @default.
• W1978155012 cites W2156888511 @default.
• W1978155012 cites W4250647894 @default.
• W1978155012 cites W4254695749 @default.
• W1978155012 doi "https://doi.org/10.1016/j.clinthera.2009.08.011" @default.
• W1978155012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19808125" @default.
• W1978155012 hasPublicationYear "2009" @default.
• W1978155012 type Work @default.
• W1978155012 sameAs 1978155012 @default.
• W1978155012 citedByCount "58" @default.
• W1978155012 countsByYear W19781550122012 @default.
• W1978155012 countsByYear W19781550122013 @default.
• W1978155012 countsByYear W19781550122014 @default.
• W1978155012 countsByYear W19781550122015 @default.
• W1978155012 countsByYear W19781550122016 @default.
• W1978155012 countsByYear W19781550122017 @default.
• W1978155012 countsByYear W19781550122018 @default.
• W1978155012 countsByYear W19781550122019 @default.
• W1978155012 countsByYear W19781550122020 @default.
• W1978155012 countsByYear W19781550122021 @default.
• W1978155012 countsByYear W19781550122022 @default.
• W1978155012 countsByYear W19781550122023 @default.
• W1978155012 crossrefType "journal-article" @default.
• W1978155012 hasAuthorship W1978155012A5003855926 @default.
• W1978155012 hasAuthorship W1978155012A5012973322 @default.
• W1978155012 hasAuthorship W1978155012A5031396369 @default.
• W1978155012 hasAuthorship W1978155012A5032317621 @default.
• W1978155012 hasAuthorship W1978155012A5043093313 @default.
• W1978155012 hasAuthorship W1978155012A5055936518 @default.
• W1978155012 hasAuthorship W1978155012A5066686056 @default.
• W1978155012 hasAuthorship W1978155012A5081667069 @default.
• W1978155012 hasConcept C126322002 @default.
• W1978155012 hasConcept C134018914 @default.
• W1978155012 hasConcept C168563851 @default.
• W1978155012 hasConcept C2777180221 @default.
• W1978155012 hasConcept C2779306644 @default.
• W1978155012 hasConcept C2779908123 @default.
• W1978155012 hasConcept C2780473172 @default.
• W1978155012 hasConcept C2780668416 @default.
• W1978155012 hasConcept C2781232474 @default.
• W1978155012 hasConcept C2910068830 @default.
• W1978155012 hasConcept C555293320 @default.
• W1978155012 hasConcept C71924100 @default.
• W1978155012 hasConcept C95190672 @default.
• W1978155012 hasConceptScore W1978155012C126322002 @default.
• W1978155012 hasConceptScore W1978155012C134018914 @default.
• W1978155012 hasConceptScore W1978155012C168563851 @default.
• W1978155012 hasConceptScore W1978155012C2777180221 @default.
• W1978155012 hasConceptScore W1978155012C2779306644 @default.
• W1978155012 hasConceptScore W1978155012C2779908123 @default.
• W1978155012 hasConceptScore W1978155012C2780473172 @default.
• W1978155012 hasConceptScore W1978155012C2780668416 @default.
• W1978155012 hasConceptScore W1978155012C2781232474 @default.
• W1978155012 hasConceptScore W1978155012C2910068830 @default.
• W1978155012 hasConceptScore W1978155012C555293320 @default.
• W1978155012 hasConceptScore W1978155012C71924100 @default.
• W1978155012 hasConceptScore W1978155012C95190672 @default.
• W1978155012 hasIssue "8" @default.
• W1978155012 hasLocation W19781550121 @default.
• W1978155012 hasLocation W19781550122 @default.
• W1978155012 hasOpenAccess W1978155012 @default.
• W1978155012 hasPrimaryLocation W19781550121 @default.
• W1978155012 hasRelatedWork W1983641721 @default.
• W1978155012 hasRelatedWork W1997132417 @default.
• W1978155012 hasRelatedWork W2026226896 @default.
• W1978155012 hasRelatedWork W2066345847 @default.
• W1978155012 hasRelatedWork W2095179743 @default.
• W1978155012 hasRelatedWork W2197938513 @default.

• next